Use of a CD28 binding substance for making a pharmaceutical composition

Abstract

The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.

1 . The use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells in vitro and/or in vivo.  
     
     
         2 . The use in particular according to  claim 1  for the treatment and/or prophylaxis of autoimmune diseases and/or inflammatory reactions.  
     
     
         3 . The use in particular according to  claim 1  for the treatment of the Guillain-Barré syndrome (GBS) or of the chronic demyelinating polyneuropathy (CDP).  
     
     
         4 . The use according to  claim 1 , wherein the mAb can be produced by that a non-human mammal is immunized with CD28 or a partial sequence herefrom, in particular the C′-D loop, cells being taken from the non-human mammal and hybridoma cells being produced from the cells, and the thus obtained hybridoma cells being selected such that in their culture supernatant there are mAbs superagonistically binding to CD28.  
     
     
         5 . The use according to  claim 1 , wherein the mimicry compound is obtainable in a screening method, a prospective mimicry compound or a mixture of prospective mimicry compounds being subjected to a binding assay with CD28 or a partial sequence herefrom, in particular the C′-D loop, and substances binding to CD28 or to the partial sequence herefrom being selected, possibly followed by an assay for testing for superagonistic stimulation of several to all sub-groups of the T lymphocytes.  
     
     
         6 . The use according to  claim 1 , wherein the mAb is obtainable from hybridoma cells, as filed under the DSM numbers DSM ACC2531 (mAb: 9D7 or 9D7G3H11) or DSM ACC2530 (mAb: 5.11A or 5.11A1C2H3).  
     
     
         7 . The use according to  claim 1 , wherein the mAb or the mimicry compound comprises one or more of the sequences Seq. ID 9, 11, 13 and/or 15, or one or more sequences Seq. ID 10, 12, 14, 16 or one or more of the sequences 18 and/or 19, or sequences being homologous hereto.  
     
     
         8 . A method for the treatment or prophylaxis of a disease according to  claim 2 , wherein either 
 to a patient is administered a pharmaceutical composition comprising a CD28-specific superagonistic monoclonal antibody or a mimicry compound hereto and in a galenic preparation for a defined and suitable form of administration, for instance IV injection, or    from a patient is taken a body liquid, in particular blood comprising T lymphocytes or precursor cells hereto, and the body liquid, possibly after a processing step, is reacted with a CD28-specific superagonistic monoclonal antibody or a mimicry compound hereto, and the thus treated body liquid is again administered to the patient, for instance by IV injection.